STRATEGIC COLLABORATION AGREEMENT --------------------------------- This Agreement is made and entered into on the 28th day of April 2003, between Peter Halmos & Sons, Inc. ("PHS") and ParkerVision, Inc. ("ParkerVision" or the "Company"). WHEREAS,...Strategic Collaboration Agreement • May 12th, 2003 • Parkervision Inc • Household audio & video equipment • Florida
STRATEGIC ALLIANCE AGREEMENTStrategic Collaboration Agreement • April 6th, 2017 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Texas
This Strategic Collaboration Agreement (“Agreement”), effective as of the 23rd day of September, 2016 (“Effective Date”), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and Adaptimmune LLC, with a place of business located at 2001 Market Street, Philadelphia, PA 1903, USA (“Adaptimmune”); and Adaptimmune Limited, with a place of business at 101 Milton Park, Abingdon, Oxfordshire, OX14 4RY (“Adaptimmune Limited”) (MD Anderson and Adaptimmune each a “Party” and collectively the “Parties”).
STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • January 8th, 2021 • 4D Pharma PLC • Pharmaceutical preparations • Texas
This Strategic Collaboration Agreement ("Agreement"), effective as of the 10th day of November, 2017 ("Effective Date"), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA ("MD Anderson"), a member institution of The University of Texas System ("System") and 4D pharma plc with a place of business located at 9 Bond Court Leeds LS1 2JZ, United Kingdom ("Company") (MD Anderson and Company each a "Party" and collectively the "Parties").
Strategic Collaboration Agreement between Weichai Power Co, Ltd. and Power Solutions International, Inc.Strategic Collaboration Agreement • April 7th, 2017 • Weichai America Corp. • Engines & turbines
AMENDMENT NO. 1 TO STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • August 18th, 2003 • Palm Inc • Computer terminals
This Amendment No. 1 to Strategic Collaboration Agreement (the “First Amendment”) is made and entered into this 23rd day of July, 2003 (the “First Amendment Execution Date”) by and between PalmSource, Inc. (“PalmSource”), a Delaware corporation with a place of business at 1240 Crossman Avenue, Sunnyvale, California 94089-1116, PalmSource Overseas Limited, a company organized and existing under the laws of Cayman Islands, with its registered office at West Wing Building, Harbour Drive, George Town, Grand Cayman, Cayman Islands, British West Indies (referred to individually as “PalmSource Cayman” or collectively with PalmSource, Inc. as “PalmSource”), and Palm, Inc., a Delaware corporation with a place of business at 400 N. McCarthy Boulevard, Milpitas, CA 95035 (“Palm” or “Licensee”).
Strategic Collaboration Agreement Between Isis Pharmaceuticals, Inc., And AstraZeneca ABStrategic Collaboration Agreement • June 10th, 2016 • Ionis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This STRATEGIC COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the 31st day of July, 2015 (the “Execution Date”) by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”), and AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Södertälje, Sweden (“AstraZeneca”). AstraZeneca and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices, exhibits and schedules are a part of this Agreement.
STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • August 18th, 2003 • Palm Inc • Computer terminals • California
This Strategic Collaboration Agreement (“Agreement”) is made and entered into between and among PalmSource, Inc., a Delaware corporation with a place of business at 1240 Crossman Avenue, Sunnyvale, California 94089-1116, Palm Platform Overseas Limited, a company organized and existing under the laws of Cayman Islands, with its registered office at West Wing Building, Harbour Drive, George Town, Grand Cayman, Cayman Islands, British West Indies (referred to individually as “PalmSource Cayman” or collectively with PalmSource, Inc. as “PalmSource”), and Palm, Inc. (“Palm” or “Licensee”), a Delaware corporation with a place of business at 400 N. McCarthy Boulevard, Milpitas, CA 95035. This Agreement is executed as of June 3, 2003 (“Execution Date”) and is effective as of the Effective Date (as that term is defined below).
AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • November 20th, 2020 • Nanobiotix S.A. • Pharmaceutical preparations • Texas
Dated November 5, 2020 Affimed GmbH and Artiva Biotherapeutics, Inc. Strategic Collaboration AgreementStrategic Collaboration Agreement • April 8th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Strategic Collaboration Agreement (Agreement) is made and entered into as of November 5, 2020 (the Effective Date) by and between Affimed GmbH, a German corporation having its principal office at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (Affimed) and Artiva Biotherapeutics, Inc. (Artiva), a US corporation having its principal office at, 4747 Executive Drive #1150, San Diego, CA 92121, USA (Artiva), (Affimed and Artiva each a Party and together the Parties).
STRATEGIC COLLABORATION AGREEMENT between FORESIGHT DIAGNOSTICS, INC. and ALLOGENE THERAPEUTICS, INC. Dated as of January 3, 2024 STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Strategic Collaboration Agreement (this “Agreement”) is effective as of January 3, 2024 (the “Effective Date”) by and between Foresight Diagnostics, Inc., having a principal place of business at 2865 Wilderness Place, Boulder, CO 80301 (“Foresight”), and Allogene Therapeutics, Inc., having a principal place of business at 210 East Grand Avenue, South San Francisco, CA 94080 (“Company”). Foresight and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
STRATEGIC COLLABORATION AGREEMENT between NESTEC LTD. and AIMMUNE THERAPEUTICS, INC.Strategic Collaboration Agreement • March 15th, 2017 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This STRATEGIC COLLABORATION AGREEMENT (this “Agreement”) is made as of November 3, 2016, by and between NESTEC LTD., a limited company organized and existing under the laws of Switzerland, having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”), and Aimmune Therapeutics, Inc., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005, USA (“Aimmune”). NHSc and Aimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
STRATEGIC COLLABORATION AGREEMENT BETWEEN CHEVRON ENERGY SOLUTIONS, LP AND SATCON TECHNOLOGY CORPORATIONStrategic Collaboration Agreement • May 14th, 2002 • Satcon Technology Corp • Semiconductors & related devices
Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT TO STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • October 7th, 2021 • 4D Pharma PLC • Pharmaceutical preparations • Texas
This AMENDMENT TO THE STRATEGIC COLLABORATION AGREEMENT (“Amendment”) is effective this 24th day of February 2021 (the “Amendment Effective Date”) by and between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and 4D PHARMA PLC, with a place of business located at 9 Bond Court Leeds LS1 2JZ, United Kingdom (“Company”). MD Anderson and Company are sometimes collectively referred to herein as the “Parties” and separately as a “Party.”
THIS AGREEMENT SHALL ONLY CONSTITUTE A BINDING AGREEMENT WHEN FULLY SIGNED BY ALL PARTIES AND EXCHANGED BETWEEN THEM. FIRST AMENDMENT OF STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • December 16th, 2019 • Ww International, Inc. • Services-personal services • New York
This First Amendment of Strategic Collaboration Agreement (this “Amendment”) is made and effective as of this 15th day of December, 2019 (the “Effective Date”), and is by and among, on the one hand, WW International, Inc. (formerly known as Weight Watchers International, Inc.), a Virginia corporation, having an address at 675 Avenue of the Americas, 6TH Floor, New York, New York 10010 (“WW”); and Oprah Winfrey, an individual having a mailing address at c/o Harpo, Inc. 1041 North Formosa Avenue, West Hollywood, CA 90046 (“OW”). Each of WW and OW is referred to herein as a “Party” and, collectively, as the “Parties”.
STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • April 21st, 2023 • MedTech Acquisition Corp • Services-medical laboratories • Texas
This Strategic Collaboration Agreement (“Agreement”), effective as of the 2nd day of March, 2021 (“Effective Date”), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and Surefire Medical Inc., dba TriSalus™ Life Sciences with a place of business located at 6272 W. 91st Avenue, Westminster, CO (“Company”) (MD Anderson and each a “Party” and collectively the “Parties”).
STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • March 13th, 2014 • Pure Bioscience, Inc. • Miscellaneous chemical products • California
THIS STRATEGIC COLLABORATION AGREEMENT (this “Agreement”), effective as of December 11, 2013 (the “Effective Date”), is made by and between Pure Biosciences, Inc., a Delaware corporation having a place of business at 1725 Gillespie Way, San Diego, CA 92020 (“Pure”), and Intercon Chemical Company, a Missouri S corporation having a place of business at 1100 Central Industrial Drive, St. Louis, MO 63110, and its Affiliates (as defined below) (“ICC”). Pure and ICC may each be referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT between SOCIÉTÉ DES PRODUITS NESTLÉ S.A. and AIMMUNE THERAPEUTICS, INC.Strategic Collaboration Agreement • February 5th, 2020 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT (this “Agreement”) is made as of February 4, 2020 (the “Effective Date”), by and between Société des Produits Nestlé S.A., a company organized and existing under the laws of Switzerland and the successor to Nestec Ltd., having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”), and Aimmune Therapeutics, Inc., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005, USA (“Aimmune”). NHSc and Aimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have caused this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date. For and on behalf of Nektar Therapeutics: Signature: /s/...Strategic Collaboration Agreement • February 28th, 2020 • Nektar Therapeutics • Pharmaceutical preparations
STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • March 13th, 2013 • Solazyme Inc • Industrial organic chemicals • New York
This Strategic Collaboration Agreement (“Agreement”) is entered into as of November 13, 2012 (the “Effective Date”), by and between Archer-Daniels-Midland Company, a Delaware company with offices at 4666 Faries Parkway, Decatur, Illinois 62526 (“ADM”) and Solazyme, Inc., a Delaware company with a principal place of business at 225 Gateway Boulevard, South San Francisco, CA 94080 (“Solazyme”).
TO AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • April 8th, 2022 • Nanobiotix S.A. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) is entered into as of June 4, 2021 (“Amendment No. 1 Effective Date”) by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“UT System”) and Nanobiotix S.A., with a place of business located at 60 Rue de Wattignies, 75012 Paris, France Nanobiotix (“Nanobiotix”) (MD Anderson and Nanobiotix each a “Party” and collectively the “Parties”).
STRATEGIC COLLABORATION AGREEMENT BETWEEN EPIX MEDICAL, INC. AND SCHERING AKTIENGESELLSCHAFT DATED AS OF JUNE 9, 2000Strategic Collaboration Agreement • March 17th, 2008 • EPIX Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS STRATEGIC COLLABORATION AGREEMENT dated as of JUNE 9, 2000 (the “Agreement”) is made by and between EPIX MEDICAL, INC., a Delaware corporation having its principal place of business at 71 Rogers Street, Cambridge, Massachusetts 02142-1118 USA (“EPIX”), and SCHERING AKTIENGESELLSCHAFT, a German corporation having its principal place of business at 13342, Berlin, Germany (“Schering”).
ContractStrategic Collaboration Agreement • February 27th, 2013
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
VOLUNTARY ANNOUNCEMENT STRATEGIC COLLABORATION AGREEMENT WITH QUANTOBIOStrategic Collaboration Agreement • March 4th, 2021
This announcement is made by Suzhou Basecare Medical Corporation Limited (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.
THIS AGREEMENT SHALL ONLY CONSTITUTE A BINDING AGREEMENT WHEN FULLY SIGNED BY ALL PARTIES AND EXCHANGED BETWEEN THEM. STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • March 2nd, 2016 • Weight Watchers International Inc • Services-personal services • New York
This Strategic Collaboration Agreement (this “Agreement”) is entered into this 18th day of October, 2015, and is by and among, on the one hand, Weight Watchers International Inc., a Virginia corporation, having an address at 675 Avenue of the Americas, 6TH Floor, New York, New York 10010 (“WW”); and Oprah Winfrey, an individual having a mailing address at c/o Harpo, Inc. 1041 North Formosa Avenue, West Hollywood, CA 90046 (“OW”)”. Each of WW and OW is referred to herein as a “Party” and, collectively, as the “Parties”.
TO AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • April 24th, 2023 • Nanobiotix S.A. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) is entered into as of June 4, 2021 (“Amendment No. 1 Effective Date”) by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“UT System”) and Nanobiotix S.A., with a place of business located at 60 Rue de Wattignies, 75012 Paris, France Nanobiotix (“Nanobiotix”) (MD Anderson and Nanobiotix each a “Party” and collectively the “Parties”).
Second Amendment to Strategic Collaboration Agreement between Weichai Power Co, Ltd. and Power Solutions International, Inc.Strategic Collaboration Agreement • March 27th, 2023 • Power Solutions International, Inc. • Engines & turbines
IN WITNESS WHEREOF, the Parties have caused this Second Amendment to Agreement to be duly executed on their behalf by their duly authorized officer as of the date first written above.
STRATEGIC COLLABORATION AGREEMENT by and between TRANZYME, INC. and BRISTOL- MYERS SQUIBB COMPANY December 4, 2009Strategic Collaboration Agreement • November 19th, 2010 • Tranzyme Inc • New York
This Strategic Collaboration Agreement (this "Agreement"), dated as of December 4, 2009 (the "Effective Date"), is made by and between Tranzyme, Inc., a Delaware corporation with a place of business at 4819 Emperor Boulevard, Suite 400, Durham, North Carolina 27703 ("Tranzyme"), and Bristol-Myers Squibb Company, a Delaware corporation with a place of business at Route 206 & Province Line Road, Princeton, NJ 08543-4000 USA (together with its Affiliates, "BMS"). Each of Tranzyme and BMS may be referred to herein as a "Party" or together as the "Parties."
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Strategic Collaboration Agreement • November 2nd, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This STRATEGIC COLLABORATION AGREEMENT (the “Agreement”) is entered into as of the [•] day of October, 2020 (the “Effective Date”) by and between FUSION PHARMACEUTICALS INC., a Canadian federal corporation with its registered offices at 270 Longwood Road S, Hamilton, Ontario L8P 0A6 (“Fusion”), and ASTRAZENECA UK LIMITED, a company incorporated in England and Wales (company number 03674842) whose registered address is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom CB2 0AA (“AstraZeneca”). AstraZeneca and Fusion each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in ARTICLE 1. All attached appendices, exhibits and schedules are a part of this Agreement.
First Amendment to Strategic Collaboration AgreementStrategic Collaboration Agreement • April 1st, 2020 • Power Solutions International, Inc. • Engines & turbines
This First Amendment to Strategic Collaboration Agreement (the “First Amendment”) is made and entered into as of March 26, 2020 by and between
MICROSOFT ARTIFICIAL INTELLIGENCE & RESEARCH GROUP STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • May 8th, 2019 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances)
This Strategic Collaboration Agreement (this “Agreement”) is made and entered into as of the last signature date written below (the “Effective Date”) by and between Microsoft Corporation, a Washington corporation having its principal place of business at One Microsoft Way, Redmond, Washington, USA 98052 (“Microsoft“) and Adaptive Biotechnologies Corporation, a company having its principal place of business at 1551 Eastlake Ave E, Seattle, WA 98102 (“Adaptive”). Microsoft and Adaptive are sometimes referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED STRATEGIC COLLABORATION AGREEMENT BY AND BETWEEN...Strategic Collaboration Agreement • June 28th, 2021 • LianBio • Pharmaceutical preparations • New York
This STRATEGIC COLLABORATION AGREEMENT (the “Agreement”) is entered into as of November 17, 2020 (the “Effective Date”), by and between LianBio, an exempted company organized under the laws of the Cayman Islands (the “Company”) and Pfizer Inc., a Delaware corporation, having an address of 235 East 42nd Street, New York, New York 10017 (“Pfizer”). The Company and Pfizer each may be referred to herein individually as a “Party” or collectively as the “Parties.” All attached appendices and exhibits are a part of this Agreement.
AMENDMENT NO. 1 TO STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • March 17th, 2008 • EPIX Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the STRATEGIC COLLABORATION AGREEMENT effective as of December 22, 2001 (the “Effective Date”) is made by and between EPIX MEDICAL, INC., a Delaware corporation having its principal place of business at 71 Rogers Street, Cambridge, Massachusetts 02142-118 USA (“EPIX”), and SCHERING AKTIENGESELLSCHAFT, a German corporation having its principal place of business at 13342, Berlin, Germany (“Schering”).
STRATEGIC COLLABORATION AGREEMENTStrategic Collaboration Agreement • May 10th, 2018 • Nektar Therapeutics • Pharmaceutical preparations • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Amendment No. 1 to Strategic Collaboration AgreementStrategic Collaboration Agreement • December 16th, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”), effective as of October 18, 2021 (the “Amendment Date”), amends certain provisions of the Strategic Collaboration Agreement dated November 5, 2020 (the “Agreement”), between Affimed GmbH, a German corporation having its principal office at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”) and Artiva Biotherapeutics, Inc., a US corporation having its principal office at, 4747 Executive Drive #1150, San Diego, CA 92121, USA (“Artiva”), (Affimed and Artiva each a “Party” and together the “Parties”).
EXHIBIT 10.2 [CERTAIN INFORMATION CONTAINED HEREIN HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 OF THE SECURITIES AND EXCHANGE ACT OF 1934. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE COMMISSION.]...Strategic Collaboration Agreement • June 29th, 2000 • Epix Medical Inc • In vitro & in vivo diagnostic substances • New York
